Cure8 news brief
If approved, a vedolizumab biosimilar could increase treatment options and competitive pricing for adults with moderate-to-severe ulcerative colitis or Crohn's disease. The company already markets a natalizumab biosimilar, which is relevant to biologic-access discussions.
Adults with IBD who use or may need biologic therapies, patients on or considering vedolizumab/Entyvio or natalizumab/Tysabri, clinicians prescribing biologics, and payer/coverage stakeholders.
Polpharma Biologics is a privately held biosimilars developer that has already brought a natalizumab biosimilar (Tyruko) to market and is pursuing a vedolizumab biosimilar (PB016) with simultaneous FDA and EMA review.
The article describes PB016 as a proposed biosimilar to Takeda's Entyvio for moderately to severely active ulcerative colitis and Crohn's disease, notes Fresenius Kabi holds global commercialization rights (excluding MENA), and reports that PK/PD comparability and safety/immunogenicity data were reported as clean in the developer's filings.
Polpharma's model keeps development and manufacturing in-house while licensing commercialization to partners (Sandoz for Tyruko; Fresenius Kabi for PB016). The piece highlights the company's regulatory firsts and late-stage pipeline across autoimmune, neurology, and oncology.
This is business/industry reporting about regulatory filings, partnerships, and commercial strategy rather than a clinical study report. Acceptance for review by FDA/EMA is discussed as the current milestone; formal approvals and market availability will depend on agency decisions.
This is industry reporting based on company pipeline details and regulatory filing status; acceptance for review is not the same as regulatory approval. The article summarizes comparability claims but does not present full trial data. Commercialization depends on future regulatory decisions and partner plans.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....
If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
